23
Participants
Start Date
January 13, 2021
Primary Completion Date
June 23, 2023
Study Completion Date
June 23, 2023
M1231
M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
M1231
M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
MD Anderson Cancer Center - Clinical Cancer Prevention, Houston
NEXT Oncology, San Antonio
Princess Margaret Cancer Centre, Toronto
EMD Serono Research & Development Institute, Inc.
INDUSTRY
Merck KGaA, Darmstadt, Germany
INDUSTRY